You are here: Industry Insights > ERLEADA

News List

J&J's 2Q Pharma Sales Up 17% contractpharma
July 30, 2021
STELARA and DARZALEX sales drive growth with sales up 34% to $2.3 billion and up 59% to $1.4 billion in the quarter, respectively.
Johnson & Johnson reports 27.1% increase in Q2 2021 sales pharmaceutical-technology
July 23, 2021
Johnson & Johnson (J&J) has reported sales of $23.31bn in the second quarter (Q2) of 2021, an increase of 27.1% compared to $18.33bn in the same quarter last year.
Erleada® improves survival without damaging quality of life in prostate cancer trial europeanpharmaceuticalreview
May 31, 2021
Data shows metastatic castration-sensitive prostate cancer patients treated with Erleada® (apalutamide) were 35 percent less likely to die and had maintained quality of life.
Janssen’s Erleada maintains quality of life for prostate cancer patients pharmatimes
May 27, 2021
Janssen’s Erleada in addition to androgen deprivation therapy (ADT) maintained prostate cancer patients’ health-related quality of life (HRQoL), according to new patient-reported outcomes (PRO) data.
NICE turns down Janssen's Erleada pharmatimes
May 21, 2021
The National Institute for Health and Care Excellence (NICE) has published draft guidance rejecting Janssen's Erleada (apalutamide) with androgen deprivation therapy (ADT) for treating prostate cancer.
Johnson & Johnson 1Q Results contractpharma
April 21, 2021
Pharmaceutical sales up 10% in the quarter driven by DARZALEX, STELARA, INVEGA SUSTENNA, and IMBRUVICA.
Erleada drug combination extends progression-free survival in prostate cancer trial europeanpharmaceuticalreview
February 10, 2021
In the Phase III ACIS study, prostate cancer patients treated with a combination of Erleada® and Zytiga® plus prednisone were less likely to die than participants receiving Zytiga and prednisone.
Pfizer, Astellas' Xtandi matches J&J's Erleada with new FDA nod fiercepharma
December 18, 2019
Pfizer and Astellas' stalwart prostate cancer med Xtandi has watched as Johnson & Johnson's challenger, Erleada, picked up the lead in the metastatic, castration-sensitive form of the disease.
FDA Approves Erleada (apalutamide) for the Treatment of Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) drugs
September 23, 2019
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved Erleada (apalutamide) for the treatment of patients with ...
Janssen announces European Commission approval of ERLEADA (apalutamide) for non-metastatic castration-resistant prostate cancer patients who are at high risk of developing metastatic disease firstwordpharma
January 17, 2019
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the European Commission (EC) has granted marketing authorisation for ERLEADA® (apalutamide), a next generation oral androgen receptor inhibitor for the treatment of adult patie